Recognizing that formalized training in telemedicine is not widely offered to physicians-in-training, the American Medical Association (AMA) adopted policy during its Annual Meeting aimed at ensuring medical students and residents learn how to use telemedicine in clinical practice.
The combined analysis of 130,315 rheumatoid arthritis patients from 11 European registries did not reveal an association between invasive (malignant) melanoma and the use of biologic therapies.
Men and women with arthritis have nearly a two-fold higher prevalence of lifetime suicide attempts than those without arthritis, according to a recent study from the University of Toronto.
Blocking the type 1 interferon receptor with the monoclonal antibody anifrolumab shows promise as a treatment for moderate-to-severe systemic lupus erythematosus (SLE), according to a phase IIb study presented here.
Prescription of long-acting opioids for chronic noncancer pain was associated with an increased risk of all-cause mortality, including deaths from causes other than overdose, compared with anticonvulsants or cyclic antidepressants, according to a study appearing in the June 14 issue of JAMA.
No increased incidence of inflammatory bowel disease has been seen among patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis treated with secukinumab (Cosentyx) in the clinical trial programs for this interleukin (IL)-17A inhibitor, a researcher reported here.
A retrospective observational study of over 6000 patients with primary hyperparathyroidism (PHPT), followed in the Kaiser-Permanente system, has shown a greater need for parathyroidectomy than was previously thought.
Lancet has published the results of the U-ACT-early study assessing the efficacy of monotherapy versus combination therapy using an interleukin-6 receptor-blocking monoclonal antibody, tocilizumab, in patients with rheumatoid arthritis.
The NEJM today published the results of two phase-3 trials (UNCOVER-2 and UNCOVER-3) demonstrating the efficacy of ixekizumab (a monoclonal antibody against interleukin-17A) in the treatment of moderate-to-severe psoriasis.
The results of the PRAIRI study were presented today at EULAR 2016 in London. These early findings suggest that individuals "at-risk" to develop rheumatoid arthritis (RA) may benefit from a short course of intravenously rituximab therapy.
JAMA has reported the results of an 18-year National Inpatient Sample, a database of US non-federal hospitalizations.
Desiree van der Heidje, MD, PhD presented the results of a 16-week, phase II, dose-ranging study of tofacitinib (TOFA) in patients with active ankylosing spondylitis.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
